Cargando…

A Triptolide Loaded HER2-Targeted Nano-Drug Delivery System Significantly Suppressed the Proliferation of HER2-Positive and BRAF Mutant Colon Cancer

BACKGROUND: Colon cancer (CRC) was a malignant tumor and there were about 25% of patients with tumor metastasis at diagnosis stage. Chemotherapeutic agents for metastatic CRC patients were with great side effects and the clinical treatment results of advanced CRC were still not satisfactory. Human e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yalikong, Ayimukedisi, Li, Xu-Quan, Zhou, Ping-Hong, Qi, Zhi-Peng, Li, Bing, Cai, Shi-Lun, Zhong, Yun-Shi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989962/ https://www.ncbi.nlm.nih.gov/pubmed/33776436 http://dx.doi.org/10.2147/IJN.S287732

Ejemplares similares

Mutant HER2 needs mutant HER3 to be an effective oncogene
por: Trenker, Raphael, et al.
Publicado: (2021)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

Significance of HER2 protein expression and HER2 gene amplification in colorectal adenocarcinomas
por: Wang, Xin-Yu, et al.
Publicado: (2019)

Triptolide Transcriptionally Represses HER2 in Ovarian Cancer Cells by Targeting NF-κB
por: Ou, Chien-Chih, et al.
Publicado: (2012)

Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas
por: Li, Qingguo, et al.
Publicado: (2011)

HDAC2 promotes the EMT of colorectal cancer cells and via the modular scaffold function of ENSG00000274093.1
por: Qi, Zhi‐Peng, et al.
Publicado: (2020)

CT features of HER2-mutant lung adenocarcinomas
por: Sawan, Peter, et al.
Publicado: (2018)

Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?
por: Ishimine, Yu, et al.
Publicado: (2015)

Clinical outcomes of patients with HER2-mutant advanced lung cancer: chemotherapies versus HER2-directed therapies
por: Zhou, Jiebai, et al.
Publicado: (2020)

Prevalence and Clinicopathological Characteristics of HER2 and BRAF Mutation in Chinese Patients with Lung Adenocarcinoma
por: Shan, Ling, et al.
Publicado: (2015)

A significant response to a combination of trastuzumab and vinorelbine in HER2-negative metastatic breast cancer with HER2 V777L mutation
por: Lei, Lei, et al.
Publicado: (2019)

Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor
por: Hu, Zexi, et al.
Publicado: (2015)

HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China
por: Zhang, Xiangyan, et al.
Publicado: (2020)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013)

Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers
por: Wang, Yan, et al.
Publicado: (2018)

The uncharted role of HER2 mutant alleles in breast cancer
por: Kalra, Rashi, et al.
Publicado: (2023)

Correction: Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor
por: Hu, Zexi, et al.
Publicado: (2018)

Genomic landscape and efficacy of HER2-targeted therapy in patients with HER2-mutant non-small cell lung cancer
por: Han, Yanjie, et al.
Publicado: (2023)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

HER2 copy number as predictor of disease-free survival in HER2-positive resectable gastric adenocarcinoma
por: Liu, Zimin, et al.
Publicado: (2021)

HER2 Status in Colorectal Cancer: Its Clinical Significance and the Relationship between HER2 Gene Amplification and Expression
por: Seo, An Na, et al.
Publicado: (2014)

Prognostic and clinical significance of HER-2 low expression in early-stage gastric cancer
por: Yang, Tao, et al.
Publicado: (2022)

Recognition of HER2 expression in hepatocellular carcinoma and its significance in postoperative tumor recurrence
por: Shi, Ji‐Hua, et al.
Publicado: (2019)

Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer
por: Guarini, Chiara, et al.
Publicado: (2021)

Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas
por: Kountourakis, Panteleimon, et al.
Publicado: (2006)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

Self-expandable metallic stenting as a bridge to elective surgery versus emergency surgery for acute malignant right-sided colorectal obstruction
por: Li, Bing, et al.
Publicado: (2020)

Breast Cancer With a HER2 IHC2+ and FISH HER2/CEP17 Ratio ≥2.0 and an Average HER2 Gene Copy Number <4.0 per Tumor Cell: HER2 mRNA Overexpression Is a Rare Event
por: Liu, Yuanyuan, et al.
Publicado: (2020)

Structural investigations on mechanism of lapatinib resistance caused by HER-2 mutants
por: Verma, Sharad, et al.
Publicado: (2018)

Mechanisms of neratinib resistance in HER2-mutant metastatic breast cancer
por: Eli, Lisa D., et al.
Publicado: (2022)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022)

Clinical significance of HER2 and EGFR expression in colorectal cancer patients with ovarian metastasis
por: Li, Ji-Lin, et al.
Publicado: (2019)

Preclinical HER-2 Vaccines: From Rodent to Human HER-2
por: Lollini, Pier-Luigi, et al.
Publicado: (2013)

HER2 signaling regulates HER2 localization and membrane retention
por: Jeong, Jaekwang, et al.
Publicado: (2017)

HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients
por: Qin, Tao, et al.
Publicado: (2013)

Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients
por: Zhang, Shaohua, et al.
Publicado: (2016)

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012)

A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2- advanced breast cancer patients with HER2 mutations
por: Ma, Jing, et al.
Publicado: (2022)

Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer
por: Stenehjem, David D, et al.
Publicado: (2014)

Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy
por: Wang, Haijun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f6bfgkakm9rtu6n9fqp64miedm